Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics

Niki Karachaliou1
Rafael Rosell2

1Translational Research Unit, Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, 2Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Barcelona, Spain

Abstract: Deeper understanding of the pathobiology of non-small-cell lung cancer (NSCLC) has led to the development of small molecules that target genetic mutations known to play critical roles in the progression to metastatic disease. The discovery of epidermal growth factor receptor (EGFR) mutations in 15%–20% of lung adenocarcinomas and the associated response to EGFR tyrosine kinase inhibitors have provided a successful avenue of attack in late-stage adenocarcinomas. Use of the EGFR tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib is limited to patients who have adenocarcinomas with known activating EGFR mutations. However, the EGFR mutation testing landscape is varied and includes many screening and targeted methods, each with its own benefits and limitations. These tests can simplify the drug discovery process, make clinical trials more efficient and informative, and individualize cancer therapy. In practice, the choice of method should be determined by the nature of the sample to be tested, the testing laboratory’s expertise and access to equipment, and whether the detection of only known activating EGFR mutations, or of all possible mutations, is required. Development of companion diagnostic tests for this identification is advancing; nevertheless, the use of such tests merits greater attention.

Keywords: lung adenocarcinoma, EGFR mutations, companion diagnostics

Introduction

Lung cancer is the leading cause of cancer-related death in the United States and it accounts for more than 1 million deaths worldwide each year.1 In recent years, the diagnosis and treatment of patients with advanced lung cancer have undergone transformational changes. The current paradigm for prescribing novel targeted therapies is based on selecting patients according to the presence of specific oncogenic abnormalities in the tumor.2 The first of such abnormalities discovered in lung cancer were epidermal growth factor receptor (EGFR) kinase domain mutations; tumors with these mutations were found to be sensitive to EGFR tyrosine kinase inhibitors (TKIs).3

Aside from the primary non-small-cell lung cancer (NSCLC) driver oncogenes (KRAS, EGFR, and ALK, which are mutated in more than 5% of NSCLC), several known or potential lung cancer oncogenes are mutated in <5% of cases. However, because lung cancer is a major lethal disease, detection of a mutation that occurs even at low rates could represent many affected patients and thus should not be ignored — especially mutations that are actionable for developing new targeted therapies.4 We review the literature on the state-of-the-art treatment of EGFR-mutant NSCLC patients,
highlighting the available methods to identify those most likely to benefit from treatment with EGFR-targeted therapy.

**Targeted treatment of mutated EGFR-expressing NSCLC**

First-generation EGFR TKIs

Causative EGFR mutations, either a deletion in exon 19 or an amino acid substitution at codon 858 in exon 21 (L858R), were present in 16.6% of Spanish NSCLC patients, and more frequently in adenocarcinomas in females (30%) and never-smokers (37.7%). Gefitinib and erlotinib are first-generation reversible EGFR TKIs approved for treatment of EGFR-mutant NSCLC. Both selectively bind to the adenosine triphosphate-binding site of the receptor. A third first-generation inhibitor, icotinib, is currently undergoing clinical trials, and previous studies have demonstrated its decreased toxicity profile and similar efficacy to gefitinib. 

Gefitinib received accelerated approval in 2003 for patients with advanced NSCLC based on studies that demonstrated rare but dramatic responses in unselected patients. However, in 2005, given the lack of a significant survival benefit compared to best supportive care, US Food and Drug Administration (FDA) approval was withdrawn for all patients except those who had previously benefited from the drug.

In 2009, NSCLC patients receiving gefitinib as a first-line therapy in the IPASS trial had a longer progression-free survival (PFS) compared to those receiving carboplatin plus paclitaxel. When the impact of therapy was based on patients’ genotype, the PFS for those with EGFR-mutant tumors was significantly longer among patients who received gefitinib than those treated with chemotherapy (9.5 versus 6.3 months, hazard ratio [HR] = 0.48; 95% confidence interval [CI] = 0.36–0.64; P < 0.001). However, the median overall survival (OS) was similar in both study arms.

One year later, two subsequent Phase III trials conducted in Asian populations of EGFR-mutant positive patients confirmed the findings from the IPASS study. The North-East Japan Study Group trial demonstrated a PFS of 10.4 months with first-line gefitinib compared to 5.5 months with chemotherapy (HR = 0.30; 95% CI = 0.22–0.41; P < 0.001), although the WJTOG3405 study found a PFS of 9.2 months with gefitinib compared to 6.3 months with chemotherapy (HR = 0.489; 95% CI = 0.336–0.710; log-rank, P < 0.0001).

The OPTIMAL and EURTAC trials were published in 2011 and 2012, respectively, and they confirmed a PFS benefit for EGFR-mutant NSCLC treated with erlotinib when compared to standard chemotherapy in first-line therapy. TKI-sensitizing mutations (exon 19 deletion or exon 21 L858R mutation) were mandatory for enrollment in these studies. The OPTIMAL study demonstrated a PFS of 13.1 months with first-line erlotinib compared to 4.6 months with gemcitabine plus carboplatin (HR = 0.16; 95% CI = 0.66–0.99; P = 0.037) in a Chinese population. The EURTAC study compared standard platinum doublet chemotherapy to erlotinib in the first-line setting for EGFR-mutant NSCLC in a European population. Again, a significant improvement in PFS in favor of the erlotinib arm over standard chemotherapy (PFS 9.7 months versus 5.2 months; HR = 0.37; 95% CI = 0.25–0.54; P > 0.0001) was observed. Based on these results, in May 2013, erlotinib was approved by the US FDA for the first-line treatment of patients with NSCLC whose tumors harbor causative EGFR mutations.

Although EGFR TKIs, such as erlotinib or gefitinib, are standard treatment for patients with EGFR-mutant NSCLC, the median PFS still does not exceed 10 months and no combination therapies have yet been incorporated into clinical practice to overcome potential mechanisms of failure to single EGFR TKIs. Among patients progressing on first-generation EGFR TKIs, 50% have tumors with a secondary T790M mutation. The emergence of the T790M EGFR gatekeeper mutation and upregulation of downstream signaling by MET amplification have been described as the two main mechanisms responsible for acquired resistance. However, a Phase III trial enrolling only patients with MET-positive tumors was stopped in early March 2014 due to futility; there was no evidence to suggest a positive effect of the addition of onartuzumab to erlotinib.

In a recent report, the combination of bevacizumab and erlotinib in the first-line setting was superior to erlotinib alone in patients with EGFR-mutant NSCLC. Remarkably, the combination had a median PFS of 16.0 months versus 9.7 months for erlotinib alone (HR = 0.54; 95% CI = 0.36–0.79; P = 0.0015). Other studies, such as BELIEF (NCT01562028), and an ongoing in US trial (NCT01532089), are being carried out with the combination of erlotinib and bevacizumab with the primary objective of clarifying the role of this combination in the subgroup of EGFR-mutant NSCLC patients who also harbor the EGFR T790M mutation. These studies pave the way to move from single EGFR TKIs to combination therapy to improve outcomes in EGFR-mutant NSCLC. If the clinical benefit of the combination of EGFR TKIs with vascular endothelial growth factor (VEGF)-targeted therapies is further validated, additional research could be warranted to prevent the
occurrence of possible novel mechanisms of resistance to VEGF-targeted therapies.

Second- and third-generation EGFR TKIs
Second-generation EGFR TKIs were developed to overcome resistance to first-generation inhibitors. Currently, there are two lead second-generation EGFR TKI candidates, afatinib and dacomitinib, which are active against EGFR mutations with acquired resistance to erlotinib or gefitinib. These drugs have the advantage of forming covalent, irreversible bonds with the target, which increases their effectiveness through the prolonged inhibition of EGFR signaling. It is hypothesized that prolonged and irreversible inhibition of the receptor has the potential for further improvement in response to treatment over first-generation TKIs.

Afatinib was recently approved for the first-line treatment of EGFR-mutant NSCLC in the US and for treatment of EGFR-mutant TKI-naïve patients in Europe and Japan. The approval was based on data from the pivotal LUX-Lung 3 trial, which compared afatinib to chemotherapy with pemetrexed plus cisplatin. The trial showed that patients on afatinib had a PFS of 13.6 months versus 6.9 months for chemotherapy (HR =0.47; 95% CI =0.34–0.65; P<0.001). In the LUX-Lung 6 trial, afatinib was compared to gemcitabine plus cisplatin for patients with EGFR mutations. PFS with afatinib was 11.0 months versus 5.6 months with chemotherapy (HR =0.28; 95% CI =0.20–0.39; P<0.0001). Notably, a recent pooled analysis of these two trials revealed an OS benefit for the afatinib arm (median OS: 27.3 months versus 24.3 months; HR =0.81; 95% CI =0.66–0.99; P=0.037) with the majority of benefit observed for patients with exon 19 deletions (median OS: 31.7 months versus 20.7 months; HR =0.59; 95% CI =0.45–0.77; P<0.001). Of note, some patients with uncommon de novo T790M and exon 20 insertions appeared to derive a benefit from afatinib.

The second-generation EGFR TKI, dacomitinib, is a pan-human epidermal growth factor receptor (HER) inhibitor that irreversibly binds to EGFR, HER2, and HER4 tyrosine kinases. Preclinical studies have demonstrated antitumor activity in NSCLC cell lines with sensitive and resistant EGFR mutations. A Phase I dose-escalation study of dacomitinib in 121 patients with advanced solid tumors (57 of whom had NSCLC) established the maximum tolerated dose as 45 mg/day, with dose-limiting toxicities of stomatitis and skin toxicities. Subsequent randomized studies comparing dacomitinib with erlotinib in unselected NSCLC populations of previously treated NSCLC patients failed to demonstrate significant improvement in outcomes. However, the role of dacomitinib as a first-line therapy in patients with activating EGFR mutations has not yet been explored.

We recently reported the possible causes of resistance to EGFR TKIs in EGFR-mutant NSCLC patients: the high coexistence of the pretreatment somatic T790M mutation with a clear impact on PFS; and the role of BIM messenger RNA expression as an independent prognostic marker. Pretreatment T790M can be detected in more than 60% of patients. In fact, using a peptide nucleic acid (PNA) clamp polymerase chain reaction (PCR) assay, pretreatment T790M mutations were detected in 65.26% of patients. These results reinforce the need for second- and third-generation EGFR TKIs, without forgetting the existing data that suggest the use of erlotinib or gefitinib beyond progression, with added chemotherapy, radiotherapy, or best supportive care as a way to improve survival.

CO-1686 is a novel covalent inhibitor that irreversibly and selectively targets both the initial activating EGFR mutations and the T790M secondary acquired resistance mutation. To investigate its use as a single agent, CO-1686 is being evaluated in a Phase I/II trial in EGFR-mutant NSCLC patients previously treated with first-line gefitinib or erlotinib (NCT01526928). In the Phase I study, and based on early findings from the ongoing Phase II trial, the agent yielded a 58% overall response rate across all dose levels in trial participants with biopsy-confirmed EGFR T790M mutations. Additionally, the compound did not cause the rash and diarrhea commonly associated with earlier generations of EGFR inhibitors.

AZD9291 showed high activity in preclinical studies and was well tolerated in animal models. Xenograft studies identified a breakdown metabolite of AZD9291 called AZ5104 that is approximately five times as potent as AZD9291 itself. In the Phase I study of AZD9291 in EGFR-mutant patients resistant to standard EGFR TKIs, 50% of patients experienced tumor shrinkage and the drug worked particularly well in patients with the T790M mutation.

**Companion diagnostics**
There is a growing trend toward the extensive molecular characterization of tumors to select the most appropriate therapy. The benefits of EGFR TKI treatment can be maximized if used with clinically validated and accurate companion diagnostics. Robust and accurate assays with rapid turnaround time are preferred. Important factors in assay performance include analytic standardization, validation of reagents and methodology, laboratory experience, and involvement of the pathologist. However, recent
quality assurance studies to ascertain the mutation status of a standard panel of tumors have shown that different clinical laboratories do not correctly identify the mutation status of 100% of the panel members, even when using identical or similar testing methodologies.38,39

In July 2011, the US FDA released a draft guidance to explain its policy requiring the review and regulatory approval of companion diagnostics as essential tools to guide the use of corresponding therapies.40 The guidance, aimed at stimulating early collaborations between drug and device makers, clarified the US FDA’s definition of a companion diagnostic; it recommended the early interaction between drug and device manufacturers and the US FDA, and it identified instances in which the US FDA may approve a targeted treatment in the absence of a cleared or approved companion diagnostic. For instance, the US FDA may decide to approve a drug even though the indicated in vitro companion diagnostic device is not US FDA-approved, particularly in diseases like cancer, for which no satisfactory alternative treatments exist. In these patients, the benefits of using the drug with an unapproved or uncleared in vitro companion diagnostic are so clear as to outweigh the risks associated with the lack of an approved in vitro companion diagnostic device.

DNA mutational analysis is the preferred method to assess EGFR status. A multitude of techniques have been developed as potential alternatives to the historical standard for EGFR mutation testing – specifically, direct DNA sequencing. Direct sequencing has low sensitivity, can be complex and time consuming, and is not standardized in terms of laboratory practice.41 However, these novel techniques have varying sensitivities to detect known and de novo mutations, with differing instruments reagents, assay run times, and costs.42 The PNA-PCR clamp assay is one method capable of detecting EGFR mutations in a background of wild-type EGFR.3 This method employs fluorescent primers with preferred amplification of the mutant sequence, which is then detected by locked nucleic acids to increase specificity. The sensitivity and specificity of the PNA-PCR clamp method are 97% and 100%, respectively.43

Many commercial EGFR mutation detection kits are available, including those from Genzyme Corporation (Cambridge, MA, USA) and Qiagen NV (Venlo, The Netherlands). The Roche cobas® EGFR Mutation Test (a real-time, PCR-based diagnostic test) (Hoffman-La Roche Ltd, Basel, Switzerland) is CE-marked and identifies 41 mutations across exons 18, 19, 20, and 21. In parallel with the approval of erlotinib as a first-line treatment for patients who harbor the EGFR mutation, the US FDA announced the approval of the cobas EGFR Mutation Test as a companion diagnostic for erlotinib, making it the first US FDA-approved companion diagnostic able to detect EGFR mutations. The safety and effectiveness of the cobas EGFR Mutation Test was established through the retrospective analysis of a clinical validation study in a subset of lung cancer specimens from patients screened in the EURTAC trial.44 The test demonstrated improved sample workflow relative to the laboratory-developed tests used in the trial, enabling EGFR mutation screening in a single assay with a 1-day turnaround time. The EGFR PCR test was highly concordant (>96%) with the laboratory-developed tests to select patients for the EURTAC trial, and it showed superior sensitivity and specificity when compared with conventional Sanger sequencing.

In July 2013, the US FDA approval of the Scorpion Amplified Refractory Mutation System therascreen® EGFR Rotor-Gene® Q PCR kit (therascreen EGFR assay; Qiagen NV) was followed by the US FDA priority review of afatinib. Recently, a high concordance rate (98.0%) of the cobas EGFR assay with the therascreen EGFR assay has been demonstrated.45 In the study from Kimura et al, both assays proved to be simple, validated methods for detecting the most common, clinically significant EGFR mutations, and they proved to be helpful for appropriate treatment guidance for NSCLC patients. However, the cobas EGFR assay has two advantages over the therascreen assay: first, it takes only 8 hours to go from the tumor specimen to the results, and patients can begin the most appropriate treatment within a shorter time; second, only a very small amount of DNA is required to detect tumor mutation status.46 In Table 1, we have summarized the main techniques for EGFR mutation testing.

Testing of tumor tissue remains the recommended method for detecting the presence of causative EGFR mutations. However, little tumor tissue may be obtained by biopsy, especially in advanced NSCLC, raising the question of whether circulating tumor (ct)DNA may be used as a surrogate liquid biopsy for the noninvasive assessment of EGFR mutations. The first blood-based EGFR mutation analysis was performed in serum obtained from Japanese patients with NSCLC before gefitinib treatment, using Scorpion Amplified Refractory Mutation System technology. EGFR mutation status in tumor tissue was consistent with that in serum in 72.7% of the paired samples.46 This finding indicated the feasibility of using serum DNA for the detection of EGFR mutations, and since then, several studies have assessed EGFR mutations in serum or plasma using different methods.47-53 The rate of detection of EGFR mutations in ctDNA varies according to the method used,46,48,49,52,54-62 A large meta-analysis of 1,591 patients tested by different
methods reported a pooled sensitivity rate of 64.5%, but it was found that the results were influenced by the test method \( (P=0.04) \). \(^{6,5}\) Therefore, the sensitivity of EGFR mutation testing in ctDNA still requires further improvement.

**Conclusion**

Personalized therapy for NSCLC patients should include a genetic assessment of EGFR mutational status for individual patients. Erlotinib, gefitinib, and afatinib are currently available as treatments for patients with advanced NSCLC who harbor EGFR mutations. Until now, no head-to-head trials between these TKIs in populations with the EGFR mutation have been reported, which allows room for individual and integrated comparisons. As a result, the appropriate role of routine EGFR mutation analysis in the treatment of patients with NSCLC is constantly evolving. These issues should form the basis for new prospective clinical studies investigating new standards of care to determine which of the different EGFR TKIs is best, and to ensure adequate documentation of the patient’s EGFR mutation status in the preclinical setting, during the treatment, and during follow-up.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


